Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 10/20 | 0.47 |
| ▸ | MAOA | P21397 | 8/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107539 | 0.86 | GAA (0.46) | KDM4EGAAKMT2APKMALDH1A1 | |
| SCHEMBL7108431 | 0.83 | KDM4E (0.44) | KDM4EGAAKMT2APKMALDH1A1 | |
| SCHEMBL7110318 | 0.78 | POLB (0.58) | MAOBMAOAALDH1A1BCHEROCK2 | |
| SCHEMBL10842161 | 0.77 | GAA (0.58) | KDM4EGAAKMT2AALDH1A1 | |
| SCHEMBL19908801 | 0.76 | POLB (0.56) | KDM4EGAAKMT2APKMALDH1A1 | |
| SCHEMBL19403829 | 0.73 | KDM4E (0.58) | KDM4EGAAKMT2APKMALDH1A1 | |
| SCHEMBL17845025 | 0.72 | MCHR1 (0.64) | KDM4E | |
| SCHEMBL5046395 | 0.72 | KDM4E (0.61) | KDM4EGAAKMT2APKMALDH1A1 | |
| SCHEMBL27833486 | 0.72 | KMT2A (0.64) | GAAKMT2APKMALDH1A1 | |
| SCHEMBL7400019 | 0.71 | PKM (0.47) | KDM4EGAAKMT2APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | claimed |
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | disclosed |
| US-6448270-B1 | BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA | WARNER-LAMBERT COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | GRIN3B, OPRM1, GRIN3A | KDM4E 955/4885GAA 510/4885KMT2A 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.